Review Article

Regulation of MicroRNAs by Natural Agents: New Strategies in Cancer Therapies

Table 1

Clinical trials involving selected natural agents.

Natural agentTrial identifierPhaseCancer typeStatus

CurcuminNCT010429382BreastCompleted
NCT000944452PancreaticCompleted
NCT001928422PancreaticCompleted
NCT013339171ColorectalCompleted
NCT000274951ColorectalCompleted
NCT010355801Uterine cervicalCompleted
NCT00113841n.aMultiple myelomaCompleted
NCT01975363n.aBreastActive
NCT018598581ColorectalActive
NCT007451342RectalActive
NCT012940721ColonActive
NCT01917890n.aProstateActive
NCT011603020Head and neckActive
NCT014909961/2ColonActive
NCT020957172ProstateActive
NCT020173532EndometrialActive
NCT020646732ProstateActive
NCT00641147n.aFamilial adenomatous PolyposisActive
NCT00927485n.aFamilial adenomatous PolyposisActive
NCT019486612ColorectalActive

ResveratrolNCT002563341ColonCompleted
NCT004335761ColorectalCompleted
NCT000989691Solid tumoursCompleted
NCT01476592n.aNeuroendocrineActive

GenisteinNCT002449332BreastCompleted
NCT001180402BladderCompleted
NCT000990081BreastCompleted
NCT005845322/3ProstateCompleted
NCT003769482PancreaticCompleted
NCT00269555n.aProstateCompleted
NCT004994082ProstateCompleted
NCT000789232ProstateCompleted
NCT019857631/2ColorectalActive
NCT013253112ProstateActive
NCT011268792ProstateActive
NCT016284711/2LungActive
NCT002768350Kidney; melanomaActive
NCT011822461/2PancreaticActive

EGCGNCT004594071ProstateCompleted
NCT002339351EsophagealCompleted
NCT005738852LungCompleted
NCT003038232CervicalCompleted
NCT011053382/3ProstateCompleted
NCT005162431BreastActive
NCT009424222Multiple myelomaActive
NCT005960112ProstateActive
NCT016061242ColorectalActive
NCT00253643n.aProstateActive
NCT009177352BreastActive
NCT013603202ColorectalActive
NCT009499231BreastActive

I3CNCT00607932n.aProstateCompleted
NCT000333451BreastCompleted
NCT001009581Solid tumoursCompleted

DIMNCT004502291ProstateCompleted
NCT003057471ProstateCompleted
NCT004628133CervicalCompleted
NCT008886542ProstateActive
NCT013916892/3BreastActive